Markston International LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 15.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 63,985 shares of the company’s stock after selling 11,642 shares during the period. Markston International LLC’s holdings in Johnson & Johnson were worth $8,319,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Harding Loevner LP acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $177,000. 65.53% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $130.27 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12-month low of $115.22 and a 12-month high of $148.32. The stock has a market cap of $349,970.00, a P/E ratio of 334.03, a P/E/G ratio of 2.33 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same period last year, the company earned $1.58 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. analysts anticipate that Johnson & Johnson will post 8.08 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.58%. Johnson & Johnson’s dividend payout ratio is presently 861.54%.

Several equities research analysts have issued reports on the stock. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. JPMorgan Chase & Co. cut shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price target on the stock in a research note on Wednesday, December 20th. BMO Capital Markets raised their price target on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Finally, BTIG Research reaffirmed a “sell” rating and set a $110.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $146.16.

COPYRIGHT VIOLATION WARNING: “Markston International LLC Lowers Position in Johnson & Johnson (JNJ)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://theolympiareport.com/2018/02/13/markston-international-llc-lowers-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.